Alcohol, tobacco & other drugs in Australia

Stimulants are a group of drugs that produce stimulatory effects by increasing nerve transmission in the brain and body (Nielsen & Gisev 2017). Included in this group are:

• Amphetamines used for therapeutic purposes to treat attention deficit-hyperactivity disorder (ADHD), but may also be used non-medically.
• Methamphetamine (also referred to as methylamphetamine) – a potent derivative of amphetamine that is commonly found in 3 forms: powder (speed), base and its most potent form, crystalline (ice or crystal). Due to small structural differences, methamphetamine produces a stronger nervous system response than amphetamine (ACIC 2019a).
• 3, 4-methylenedioxymethamphetamine (MDMA) – commonly referred to as ‘ecstasy’ –  is an amphetamine derivative. (Note ecstasy may contain a range of other drugs and substances and may contain no MDMA at all).
• Cocaine – produced from a naturally occurring alkaloid found in the coca plant.

Key findings

View the Meth/amphetamine and other stimulants in Australia fact sheet >

The focus in this section is on the illicit use of meth/amphetamine and other stimulants (Box STIM1).

Availability

People who regularly use illicit drugs report that methamphetamine and other stimulants are easy to obtain in Australia.

Findings from the Illicit Drug Reporting System (IDRS) show that people who inject drugs commonly report it is ‘easy’ or ‘very easy’ to obtain methamphetamine and other stimulants. Specifically in 2022:

• Over 9 in 10 (91%) people who had recently used crystal methamphetamine reported that it was ‘easy’ or ‘very easy’ to obtain (Sutherland et al. 2022b, Figure 15).
• Over 3 in 5 (65%) people who had recently used cocaine reported that it was ‘easy’ or ‘very easy’ to obtain (Sutherland et al. 2022b).

Similarly, data from the 2022 Ecstasy and Related Drugs Reporting System (EDRS) show that most people who use ecstasy and other stimulants report that methamphetamine, ecstasy and cocaine are ‘easy’ or ‘very easy’ to obtain (Sutherland et al. 2022a). Findings show that:

• Perceived availability was the highest for crystal methamphetamine (92% of participants rated it ‘easy or very easy’ to obtain), an increase from 2021 (82%). Perceived availability for powder methamphetamine was lower which has remained stable relative to 2021 (59% of participants rated availability as it ‘easy or very easy’ to obtain).
• In 2022 a significant change in the perceived availability of ecstasy in all forms was reported relative to 2021. For capsules 49% of participants rated it ‘easy’ or ‘very easy’ to obtain, a decrease from 76% in 2021. Powder forms decreased to 42% from 68%, crystal declined to 49% from 66%, and pills to 48% from 61% in 2021.
• Perceived availability of cocaine remained stable relative to 2021; 79% of participants in 2022 who could comment rated it ‘easy’ or ‘very easy’ to obtain.
• The main approach for arranging the purchase of any illicit or non-prescribed drugs by participants in the previous 12 months was via social networking applications (73%) (such as Facebook, Wickr, WhatsApp, SnapChat, Grindr, Tinder) an increase from 2021 (71%). 69% of participants reported arranging purchases face-to-face, a decrease from 2021 (72%) (Sutherland et al. 2022a).

Data collection for 2022 took place from April–July for the EDRS and May–July for the IDRS. Due to COVID-19 restrictions being imposed in various jurisdictions during data collection periods for both the IDRS and the EDRS, interviews in 2020, 2021 and 2022 were delivered face-to-face as well as via telephone. This change in methodology should be considered when comparing data from the 2020, 2021 and 2022 samples relative to previous years.

The Australian Criminal Intelligence Commission (ACIC) collects national illicit drug seizure data annually from federal, state and territory police services, including the number and weight of seizures to inform the Illicit Drug Data Report (IDDR). According to the latest IDDR, in 2019–20, around one-third of national illicit drug seizures (39,204 or 32%) were amphetamine-type stimulants (ATS) (including MDMA).

The number of national ATS seizures has increased by 250% over the last decade, with 39,204 seizures in 2019–20, up from 11,212 in 2010–11. In 2019–20, ATS accounted for 33% of the total weight of illicit drugs seized nationally. The total weight of ATS seized nationally has increased 1,175% over the last decade, from 1,009 kilograms in 2010–11 to a record 12,865 kilograms in 2019–20.

The record 34,113 national amphetamines seizures in 2019–20 weighed a record 9,408 kilograms and accounted for 87% of the number and 73% of the weight of ATS seized nationally this reporting period (ACIC 2021). Research (ACIC 2019b) has shown the impact of seizures on consumption – see Supply reduction – Prohibited substances (ACIC 2021; tables S1.18 and S1.19).

In 2019–20, there were 1,377 amphetamine-type stimulant (excluding MDMA) detections at the Australian border, weighing 5,272 kilograms. The number of MDMA (ecstasy) detections at the Australian border was 2,308 in 2019–20, while the weight of MDMA detected was 1,291 kilograms. The number of national MDMA seizures was 4,981 in 2019–20, and the total weight of MDMA seized nationally was 3,214 kilograms, accounting for 13% of the number and 25% of the weight of ATS seized nationally (ACIC 2021).

Over the last decade, the number of cocaine detections at the Australian border increased by 447%, from 486 in 2010–11 to 2,660 in 2019–20. The weight of cocaine detected has increased by 9%, from 701 kilograms in 2010–11 to 763 kilograms in 2019–20 (ACIC 2021).

The number of national cocaine seizures has increased by 372% over the last decade, from 1,217 in 2010–11 to a record 5,750 in 2019–20. The weight of cocaine seized nationally increased by 138% over the same period, from 662 kilograms in 2010–11 to 1,573 kilograms in 2019–20 (ACIC 2021).

Consumption

There are differences in trends and patterns of consumption in Australia according to the type of stimulant used.

Data collection for 2022 took place from April–July for the EDRS and May–July for the IDRS. Due to COVID-19 restrictions being imposed in various jurisdictions during data collection periods for both the IDRS and the EDRS, interviews in 2020, 2021 and 2022 were delivered face-to-face as well as via telephone. This change in methodology should be considered when comparing data from the 2020, 2021 and 2022 samples relative to previous years.

Meth/amphetamine

• 1.3% of people aged 14 and over in Australia reported using meth/amphetamine in the last 12 months (Figure STIM1).
• 31% of participants in the EDRS reported use of any form of methamphetamine in the previous 6 months (Sutherland et al. 2022a).
• 81% of participants in the IDRS reported use of any form of methamphetamine in the previous 6 months (Sutherland et al. 2022a).

Self-reported data on meth/amphetamine consumption in the general Australian population has been declining since it peaked at 3.4% in 2001. There was a substantial decrease in the recent use of meth/amphetamine among people aged 20–29 (from 11.2% in 2001 to 2.4% in 2019), however, there were slight increases for people aged 40 and over (AIHW 2020, Table 4.72). It is possible that self-report surveys underestimate the true extent of meth/amphetamine use, particularly in the context of the stigmas that exist around its consumption (AIHW 2020).

In 2013, ‘crystal/ice’ replaced powder as the main form of meth/amphetamine used in the previous 12 months. In 2019, this trend continued with 50% of people who used meth/amphetamine reporting that crystal/ice was the main form used in the previous 12 months (AIHW 2020). While overall recent meth/amphetamine use declined between 2013 and 2019, the proportion using crystal/ice remained relatively stable (AIHW 2020).

Participants in the EDRS reported a decrease in the use of crystal methamphetamine in the preceding 6 months (29% in 2012 to 18% in 2022) (Sutherland et al. 2022a, Figure 16).

Figure STIM1: Recentᵃ use of meth/amphetamine, cocaine or ecstasy, people aged 14 and over, by age and sex, 2001 to 2019 (per cent)

View data tables >

Ecstasy

The 2019 NDSHS found:

• 3.0% of people aged 14 and over in Australia used ecstasy in the previous 12 months, a significant increase since 2016 (2.2%) (Figure STIM1).
• A higher proportion of males than females reported recent ecstasy use in 2019 (3.9% compared with 2.0%).
• The increase in recent ecstasy use since 2016 was largely driven by a significant increase reported for males (from 2.6% in 2016 to 3.9% in 2019). In particular, there were significant increases for males aged 20–29 (from 7.4% in 2016 to 12.1% in 2019) and 30–39 (from 3.2% in 2016 to 4.9%).
• Between 2007 and 2016, recent use of ecstasy declined from a high of 3.5% in 2007 to 2.2% in 2016. However, in 2019 the proportion for the recent use of ecstasy had returned to the 2010 level (3.0%) (AIHW 2020, Table 4.63).
• There was a significant increase in lifetime use of ecstasy between 2016 (11.2%) and 2019 (12.5%). This was largely driven by significant increases for people aged 40–49 (from 14.8% to 19.4%) and 50 and over (2.4% to 3.2%) (AIHW 2020, Table 4.61).

In 2022 ecstasy and cannabis were the most common reported drug of choice for participants of the EDRS who regularly use ecstasy and other stimulants (Sutherland et al. 2022a, Figure 1). EDRS participants indicated that when the past 6 months was compared with the previous year:

• Ecstasy use was reported by 88% of participants, a decline from 95% of participants in 2021 (Sutherland et al, 2022a).

Cocaine

The 2019 NDSHS found:

• 4.2% of people aged 14 and over in Australia used cocaine in the last 12 months, a significant increase since 2016 (2.5%)
• recent cocaine use in 2019 was higher in males (5.5%) than females (3.0%)
• recent cocaine use increased significantly between 2016 and 2019 across all age groups, except 14–19 year olds
  • the increase in recent use was largely driven by the significant increases reported for males, in particular for males aged 20–29 (from 7.3% to 14.4%) (AIHW 2020, Table 4.56)
• in 2019, the proportion of people who reported recent use of cocaine was at the highest level reported since 2001–in 2019 it was 3 times higher than the level reported in 2001 (1.3% in 2001 compared with 4.2% in 2019 (AIHW 2020, Table 4.56).

There was a significant increase in lifetime use of cocaine between 2016 (9%) and 2019 (11.2%) (AIHW 2020, Table 4.2). This was driven largely by increases for people aged 20–29 (from 13.2% to 19.5%), 40–49 (from 12.0% to 15.3%) and 50 and older (3.4% to 4.3%) (AIHW 2020).

For participants of the EDRS, cocaine was the third most commonly used stimulant drug (after ecstasy and cannabis) with 79% reporting past 6 month use in 2022, remaining stable relative to 2021 (80%) (Sutherland et al. 2022a).

Geographic trends

Data from the National Wastewater Drug Monitoring Program (NWDMP) show that the population-weighted average consumption of stimulant drugs varies based on drug type and geographic area.

Methylamphetamine continued to have the highest population-weighted average consumption of any illicit drug monitored by the program (ACIC 2023). Data from Report 18 of the NWDMP indicate that nationally in August 2022 compared to April 2022:

• Consumption of methylamphetamine decreased in both capital city and regional sites.
• Average methylamphetamine consumption was similar in capital city and regional sites (ACIC 2023).

The estimated weight of methylamphetamine consumed increased from 8,405 kilograms in 2016–17 to 11,516 kilograms in 2018–19, before declining to 9,018 kilograms in 2021–22 (ACIC 2023, Figure STIM2).  The total estimated consumption of methylamphetamine increased by 2% between August 2021 and August 2022.

For state and territory data, see the National Wastewater Drug Monitoring Program reports.

Figure STIM2: Estimated consumption of methylamphetamine in Australia based on detections in wastewater, 2021 to 2022

(a) 'Average consumption' refers to estimated population-weighted average consumption.

Note: Report 18 covers 57% of the Australian population (58 wastewater treatment sites).

Source: AIHW, adapted from, ACIC 2023.

MDMA consumption is low across the country, relative to other illicit drugs and has been declining for the past 2 years. The estimated weight of MDMA consumed annually in Australia steadily increased from 1,162 kilograms in 2017–18 to 2,630 kilograms in 2019–20 before decreasing to 723 kilograms in 2021-22 (a 41% decrease from 2020-21) (ACIC 2023). Data from Report 18 of the NWDMP indicate that nationally:

• In August 2022, the population-weighted average consumption of MDMA in capital cities was higher than regional areas.
• Between April 2022 and August 2022, the population-weighted average consumption in both capital cities and regional areas increased (ACIC 2023).

For state and territory data, see the National Wastewater Drug Monitoring Program reports.

Cocaine consumption in Australia steadily increased from 3,057 kilograms in 2016–17 to 5,675 kilograms in 2019–20, before declining to 3,385 kilograms in 2021-22 (a 28% decrease from 2020-21) (ACIC 2023). Data from Report 18 of the NWDMP indicate that:

• Since December 2021, cocaine consumption experienced considerable decreases, with population-weighted average consumption of cocaine decreasing in both capital cities and regional areas to record lows in August 2022.
• Consumption in capital cities exceeded that in regional areas.
• The reduction in cocaine consumption is most likely due to reduced supply related to law enforcement disruptions of attempted cocaine importations in 2022 (over 6 tonnes of cocaine was seized in 2022) (ACIC 2023).

For state and territory data, see the National Wastewater Drug Monitoring Program reports.

Data from the 2019 NDSHS showed that:

• There was a significant increase in the proportion of people aged 14 and over who reported recent use of meth/amphetamine in New South Wales between 2016 and 2019 (from 0.7% to 1.1%), while for South Australia, there was a significant decrease (from 1.9% to 1.0%) (AIHW 2020, Table S.38).
• Similar proportions of people living in Major cities, Inner regional and Remote and very remote areas recently used meth/amphetamine in 2019 (1.4%, 1.3% and 1.4%, respectively). A lower proportion (0.8%) of people living in Outer regional areas reported recent use of meth/amphetamine (Figure STIM3). These findings were still apparent after adjusting for differences in age (AIHW 2020, Tables 7.15 and 7.18). Note, the estimate for Remote and very remote areas has a relative standard error of 25% to 50% and should be used with caution.  
• There was little variation in the recent use of meth/amphetamine for those living in the lowest socioeconomic areas compared with those living in the highest socioeconomic areas (1.4% and 1.5%, respectively) (Figure STIM3). This finding was still apparent after adjusting for differences in age (AIHW 2020).
• There were significant increases in the recent use of cocaine between 2016 and 2019 in New South Wales (from 3.4% to 5.0%), Victoria (from 2.5% to 5.2%) and Queensland (from 2.1% to 3.6%) (AIHW 2020, Table S42).
• There were also significant increases in the recent use of ecstasy between 2016 and 2019 in New South Wales (from 1.9% to 3.1%) and Victoria (from 2.4% to 3.7%).
• Cocaine and ecstasy use were higher among those who lived in Major cities or the highest socioeconomic areas (Figure STIM3). These findings were still apparent after adjusting for differences in age (AIHW 2020, Table S36).

Figure STIM3: Recent^a use of meth/amphetamine, cocaine or ecstasy, by remoteness area or socioeconomic area, people aged 14 and over, 2010 to 2019 (percent)

View data tables >

International comparisons

The National Wastewater Drug Monitoring Program (NWDMP) recently examined average stimulant consumption (amphetamine, methylamphetamine, cocaine, and MDMA) in Australia compared with 28 countries across Europe, Oceania, and Asia. In March/April 2021:

• Australia had the highest average total stimulant consumption of all included countries at 48 doses per 1,000 people per day, followed by Czechia and the Netherlands (both 44 doses), and Belgium (40 doses)
• Australia had the highest average consumption of methylamphetamine (41 doses per 1,000 people per day), followed by Czechia (36 doses) and Latvia (19 doses)
• Cocaine consumption in Australia ranked 15^th of 26 countries at 5.0 doses, compared with 26 doses for the highest-ranked country (Belgium) and 0.61 doses for the lowest-ranked country (New Zealand).
• Australia ranked 5^th in MDMA consumption at 1.5 doses per 1,000 people per day, behind the Netherlands, France, Poland and Portugal (ranging from 4.8 doses to 1.5 doses).

When examining each drug type as a proportion of total combined stimulant consumption:

• Most stimulant consumption in Australia related to methylamphetamine use, which is similar to New Zealand, South Korea, Slovakia, Czechia, Latvia and Turkey. Most other European countries had higher use of amphetamine and cocaine.
• Average consumption in Australia was proportionally higher for methamphetamine than MDMA, which is consistent with most other countries.
• Cocaine consumption in Australia was proportionally higher than the use of MDMA. This was consistent with most participating countries, but was the opposite of New Zealand (where MDMA consumption was higher than cocaine) (ACIC 2022b).

Poly drug use

Poly drug use is defined as the use of mixing or taking another illicit or licit drug whilst under the influence of another drug. In 2019, the NDSHS showed that only 8.1% of people who reported using meth/amphetamine in the last 12 months said they did not use any other illicit drug. The most common other drugs concurrently used were cannabis (78%) and cocaine (57%). More than three-quarters exceeded the alcohol single occasion risk guideline at least monthly (76%) and over half (54%) exceeded the lifetime risk guideline (AIHW 2020, Table 1.3).

People who reported recent use of ecstasy and cocaine also reported concurrent use of cannabis (77% and 69%, respectively) and 8 in 10 exceeded the alcohol single occasion risk guideline at least monthly (83% and 82%, respectively).

Data on alcohol and other drug-related ambulance attendances are sourced from the National Ambulance Surveillance System (NASS). Monthly data for 2021 are currently available for New South Wales, Victoria, Queensland, Tasmania and the Australian Capital Territory. It should be noted that some data for Tasmania and the Australian Capital Territory have been suppressed due to low numbers. Please see the data quality statement for further information.

In 2021, the proportion of amphetamine-related ambulance attendances where multiple drugs were involved (excluding alcohol) ranged from 33% of attendances in Queensland to 48% of attendances in Victoria (Table S1.10).

For related content on multiple drug involvement see Impacts: Ambulance attendances.

Harms

The short and long-term effects associated with the use of methamphetamine and other stimulants are provided in Table STIM1.

Source: Adapted from ACIC 2019a; Darke, Kaye & Duflou 2017; NSW Ministry of Health 2017.

Burden of disease and injury

The Australian Burden of Disease Study, 2018, found that amphetamine use was responsible for 0.7% of the total burden of disease and injuries in Australia in 2018 and 24% of the total burden due to illicit drug use (AIHW 2021b) (Table S2.5).

Of the burden due to amphetamine use, drug use disorder (excluding alcohol) contributed 32%, poisoning 17% and suicide and self-inflicted injuries 5.4%. Other contributors to the burden due to amphetamine use included road traffic injuries–motor vehicle occupants and motorcyclists (3.0% each) (AIHW 2021b).

Cocaine use contributed 0.3% of the total burden of disease and injuries in 2018 and 10.9% of the total burden due to illicit drug use (Table S2.5). Of the burden due to cocaine use, suicide and self-inflicted injuries accounted for 6.4% and drug use disorder (excluding alcohol) 10.6% (AIHW 2021b).

Ambulance attendances

Data on alcohol and other drug-related ambulance attendances are sourced from the National Ambulance Surveillance System (NASS). Monthly data are presented in 2021 for people aged 15 years and over for New South Wales, Victoria, Queensland, Tasmania and the Australian Capital Territory.

In 2021, for amphetamine-related ambulance attendances (including crystal methamphetamine) in these jurisdictions:

• Rates of attendances ranged from 49.3 per 100,000 population in Tasmania to 85.2 per 100,000 population in Victoria.

In New South Wales, Victoria and Queensland (numbers for Tasmania and the Australian Capital are too small to report):

• 3 in 5 (63%) of total attendances were for males.
• The highest rates of attendances were in people aged 25–34:
  • Victoria (1,714 attendances, 164.4 per 100,000 population
  • Queensland (1,040 attendances, 143.0 per 100,000 population) New South Wales (1,515 attendances, 126.0 per 100,000 population) (Table S1.9).

Figure STIM4: Ambulance attendances for amphetamines (any), cocaine and ecstasy, by age, sex and selected states and territories, 2021

Hospitalisations

Drug-related hospitalisations are defined as hospitalisations with a principal diagnosis relating to a substance use disorder or direct harm relating to use of selected substances (AIHW 2018).

AIHW analysis of the National Hospital Morbidity Database (NHMD) showed that, among all drug-related hospitalisations in 2020–21:

• One in 10 were for amphetamines and other stimulants (10% or 15,100 hospitalisations). Within this category, over 4 in 5 hospitalisations were for methamphetamine (82% or 12,400 hospitalisations)
• Just over 1% were for cocaine (1.2% or 1,800 hospitalisations) (Table S1.13).

This represents a rate of 48.4 hospitalisations per 100,000 population for methamphetamine and 7.0 per 100,000 for cocaine (Table S1.13). Around 2 in 3 hospitalisations for cocaine ended with a same-day discharge (67% or 1,200 hospitalisations). By contrast, around 7 in 10 hospitalisations for methamphetamine involved an overnight stay (71% or 8,800) (Table S1.12).

In 2020–21, most hospitalisations occurred in Major cities for both methamphetamine (71% or 8,800 hospitalisations) and cocaine (94% or 1,700 hospitalisations) (Table S1.14).

• Accounting for differences in population size, the rates of hospitalisations for methamphetamine were similar in Remote and very remote areas and in Major cities (48.4 and 47.2 hospitalisations per 100,000 population, respectively).

• The rate of hospitalisations for cocaine was highest in Major cities (9.0 per 100,000 population, compared with 1.5 and 0.9 per 100,000 in Inner regional and Out regional areas, respectively) (Table S1.14).

In the 6 years to 2020–21:

• The number of methamphetamine-related hospitalisations increased between 2015–16 (9,300 hospitalisations or 38.8 per 100,000 population) and 2019–20 (14,100 hospitalisations or 55.0 per 100,000), then declined in 2020–21.
• The number of cocaine-related hospitalisations steadily increased between 2015–16 (780 hospitalisations or 3.2 per 100,000 population) and 2018–19 (1,200 hospitalisations or 4.8 per 100,000). These figures stabilised in 2019–20 (1,300 hospitalisations or 5.0 per 100,000), before increasing further in 2020–21 (1,800 or 7.0 per 100,000) (Table S1.13; Figure IMPACT4).

The finding for cocaine is consistent with analysis of the NHMD by the National Drug and Alcohol Research Centre (NDARC). This analysis showed that, accounting for population growth and ageing, the rate of cocaine-related hospitalisations increased almost 6-fold between 2010–11 (0.8 per 100,000 population) and 2018–19 (4.5 per 100,000 population). A significant increased was also observed between 2019–20 (4.8 per 100,000 population) and  2020–21 (6.7 per 100,000 population) (Chrzanowska et al. 2022a).

Deaths

Drug-induced deaths are determined by toxicology and pathology reports and are defined as those deaths that can be directly attributable to drug use. This includes deaths due to acute toxicity (for example, drug overdose) and chronic use (for example, drug-induced cardiac conditions) (ABS 2021).

The rate of drug-induced deaths related to methamphetamine and other stimulants has increased rapidly in recent years. 

See also Health impacts: Drug-induced deaths for more information.

• AIHW analysis of the AIHW National Mortality Database shows that the death rate for all psychostimulants (including amphetamines, methamphetamine, ecstasy/MDMA and caffeine) in 2021 was almost 4 times higher than that in 2000 (1.8 deaths compared with 0.5 deaths per 100,000 population, respectively). Over the same period, the rate of drug-induced deaths involving cocaine increased from 0.1 deaths to 0.3 deaths per 100,000 population (Table S1.1).
• Estimates by the National Drug and Alcohol Research Centre (NDARC) showed that, in 2020, there were 524 drug-induced deaths involving amphetamines –a rate of 2.1 deaths per 100,000 people. This is an increase from 104 deaths (0.5 deaths per 100,000) in 2011, and the highest rate recorded across the monitoring period (Chrzanowska et al. 2022).
• Recent research examining methamphetamine-related deaths in isolation from other stimulants found that mortality rates have almost doubled during a period of 7 years between 2009 and 2015. The most common manner of methamphetamine-related death was accidental drug toxicity; however, natural disease (e.g. coronary disease, stroke, kidney disease, and liver disease), suicide and accidents comprised more than half of the deaths (Darke, Kaye & Duflou 2017).

Treatment

Amphetamines

The AODTS NMDS provides information on treatment provided to clients by publicly funded AOD treatment services, including government and non-government organisations. Data from the AODTS NMDS showed that amphetamines were the second most common principal drug of concern in closed treatment episodes provided to clients in 2020–21. Amphetamines were the principal drug of concern in 24% of closed treatment episodes for clients’ own drug use – a similar proportion to 2019–20 (28%). Almost 4 in 5 (79%) amphetamine treatment episodes were for methamphetamine (AIHW 2022).

In 2020–21, where amphetamines were the principal drug of concern:

• Almost 2 in 3 (64%) of clients were male and around 1 in 5 (19%) clients were Indigenous Australians (AIHW 2022, tables SC.9 and SC.11).
• Most clients (69%) were aged 20–39 (AIHW 2022, Table SC.10).
• The most common source of referral for treatment was self/family (36% of treatment episodes), followed by health services (29%) (AIHW 2022, Table Drg.37).
• The most common main treatment type was counselling (41% of treatment episodes), followed by assessment only (20%) (AIHW 2022, Table Drg.36; Figure STIM5).
• Counselling has remained the most common main treatment type across the 10-year period to 2020–21 (AIHW 2022).

Figure STIM5: Treatment provided for own use of amphetamines, 2020–21 (percent)

Source: AIHW 2022, tables Drg.1, SC.11 and Drg.36.

In 2016–17, where the principal drug of concern was amphetamines, the proportion of people living in Regional and remote areas who travelled 1 hour or longer to treatment services was higher than in Major cities (31% compared with 10%) (AIHW 2019).

Ecstasy

In 2020–21, ecstasy was the principal drug of concern in less than 1% (0.3%) of closed treatment episodes provided for clients’ own drug use (AIHW 2022, Table Drg.5). Treatment episodes for ecstasy remained relatively stable over the 10-year period to 2020–21.

In 2020–21, where ecstasy was the principal drug of concern:

• 2 in 3 (66%) clients were male and 8% were Indigenous Australians (AIHW 2022, tables SC.9 and SC.11).
• Over 4 in 5 (85%) clients were aged 10–29 (AIHW 2022, Table SC.10).
• The most common source of referral was diversion from the criminal justice system (31%) followed by self/family (25%) (AIHW 2022, Table Drg.73).
• The most common main treatment type was counselling (51%), followed by assessment only (17%) (AIHW 2022, Table Drg.72).

Cocaine

In 2020–21, cocaine was the principal drug of concern in 1.1% of closed treatment episodes provided for clients’ own drug use (AIHW 2022, Table Drg.5). The proportion of treatment episodes for cocaine has remained low over the 10-year period to 2020–21, increasing from 0.3% of episodes in 2011–12 (AIHW 2022).

In 2020–21, where cocaine was the principal drug of concern:

• Over 4 in 5 (85%) clients were male and 5.4% were Indigenous Australians (AIHW 2022, tables SC.9 and SC.11).
• 1 in 2 (50%) clients were aged 20–29, and 28% were aged 30–39 (AIHW 2022, Table SC.10).
• The most common source of referral was self or family (37% of closed treatment episodes), followed by health services (24%) (AIHW 2022, Table Drg.82).
• Counselling was the most common main treatment type (49% of closed treatment episodes), followed by assessment only (21%) (AIHW 2022, Drg.81).

At-risk groups

The use of meth/amphetamine and other stimulants can be disproportionately higher for specific population groups.

• Aboriginal and Torres Strait Islander people were more than 2 times as likely to report the recent use of meth/amphetamine than non-Indigenous Australians. However, the estimate for Indigenous Australians has a relative standard error of 25% to 50% and should be used with caution.
• More than half of police detainees and prison entrants recently used methamphetamine.
• People with a mental health condition were more than 2 times as likely to report recent meth/amphetamine use than people who had not been diagnosed or treated for a mental health condition.
• Methamphetamine is the most commonly injected drug in Australia.

Policy context

Public perceptions and policy support

The NDSHS found that between 2016 and 2019, more people associated meth/amphetamine with a drug problem (46% compared with 49%) and thought it caused the most deaths (19.2% compared with 20%) (AIHW 2020, tables 9.1 & 9.3). Meth/amphetamine was reported to be the drug of most concern to the community by 2 in 5 (40%) people (AIHW 2020, Table 9.5).

National Ice Action Strategy 2015

In April 2015, the Australian Government established a National Ice Taskforce, to provide advice on the development of a National Ice Action Strategy (NIAS).

The objectives of the NIAS are to ensure that:

• families and communities have better access to information, support and tools to help them to respond to ice (methamphetamine);
• prevention messages are targeted at high-risk populations and accurate information about ice is more accessible;
• early intervention and treatment services are better tailored to respond to ice and meet the needs of the populations they serve;
• law enforcement efforts are better targeted to disrupt the supply of ice; and
• better evidence is available to drive responses to the effects of ice in our community (DoH 2017).